MUSTANG BIO, INC.
MUSTANG BIO, INC. (MBIO): 4 pipeline candidates · ~48 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
48.4 months
D/E 0.93
Lead: Phase 1
4 candidates
N/A
1 buy · 2 sells (180d)
A transparent, data-derived signal for MUSTANG BIO, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.3M
Cash
$16.3M
Quarterly Burn
$1.0M
Runway
48.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$241K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 92,790 | $68K |
| blackrock, inc. | 84,745 | $62K |
| citadel advisors llc | 53,200 | $39K |
| vanguard capital management llc | 51,408 | $37K |
| vanguard fiduciary trust co | 32,120 | $23K |
| two sigma investments, lp | 16,754 | $12K |
| sbi securities co., ltd. | 509 | $371 |
| morgan stanley | 118 | $86 |
| cullen/frost bankers, inc. | 13 | $9 |
| bnp paribas financial markets | 6 | $4 |
Showing top 10 of 18 institutional holders of MUSTANG BIO, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MUSTANG BIO, INC.'s pipeline?
MUSTANG BIO, INC. (MBIO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MUSTANG BIO, INC.'s lead drug candidate?
MUSTANG BIO, INC.'s most advanced tracked candidate is mb-101 (Phase 1) for IL13Rα2+ recurrent/refractory malignant glioma, glioblastoma (GBM), and high-grade astrocytoma.
What is MUSTANG BIO, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MUSTANG BIO, INC. has approximately 48.4 months of cash runway.
What is MUSTANG BIO, INC.'s market capitalization?
MUSTANG BIO, INC.'s market capitalization is approximately $5.3M.
Who is the CEO of MUSTANG BIO, INC.?
Dr. Manuel Litchman M.D. is the chief executive officer of MUSTANG BIO, INC. (MBIO).
Get the full picture on MUSTANG BIO, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.